Tag: Johnson & Johnson

  • FG Begins Johnson & Johnson Single Dose COVID-19 Vaccination

    FG Begins Johnson & Johnson Single Dose COVID-19 Vaccination

    The Federal Government Tuesday formally rolled out the Johnson & Johnson single dose of COVID-19 vaccination in the country.

    The government also launched the SCALES 2.0 Strategy which entails the integration of COVID-19 vaccination with childhood routine immunization for eligible adults 18 years and above, and children zero to two years respectively.

    SCALES is an acronym for service delivery, communication, accountability, logistics, electronic reporting, and supportive supervision for the ongoing COVID-19 vaccination.

    It will be done leveraging mass vaccination campaigns, routine immunization fixed sessions, outreach services and mobile services.

    The Minister of Health, Osagie Ehanire, said Nigeria had an adequate stock of the Johnson and Johnson vaccine, with over 30 million doses in stock.

    He urged all eligible persons yet to receive their vaccination to go to the nearest COVID-19 vaccination site and get vaccinated.

    “This single dose offers the same protection you get from two doses of AstraZeneca, Pfizer Bio-N-Tech and Moderna vaccines,” he said.

    He said the SCALES strategy had proven to be quite effective in ramping up COVID-19 vaccination coverage.

    Ehanire said as of February 18, Nigeria had administered over 20 million doses of COVID-19 vaccination, representing over 18 per cent of the 111,176,503 eligible population targeted for vaccination.

  • FG Flag-Off 2nd phase of COVID-19 vaccination with 177,600 doses of J&J, 4,000,080 Moderna vaccines

    FG Flag-Off 2nd phase of COVID-19 vaccination with 177,600 doses of J&J, 4,000,080 Moderna vaccines

    By Joyce Remi- Babayeju

    Today the Federal Government flagged- off the 2nd phase of the COVID-19 vaccination with 177,600 doses of Johnson and Johnson vaccines and the Moderna vaccines.

    Minister of Health, Dr. Osagie Ehanire officially  declared the 2nd phase of the vaccination toll out at the  National at the Federal Medical Centre, Jabi, Abuja.

    The Executive Director of the National Primary Health Care Development Agency, NPHCDA, Dr. Faisal Shuaibu said, ” This flag-off is necessitated by the need to create awareness on what we will be doing differently  to ensure a more successful vaccination campaign.”

    While commending the synergy and dedication among all health workers, allied government parastatals, the media and other stakeholders  to fight the virus noted the country could not have succeeded in fully utilizing the COVID-19 vaccines we received from COVAX facility for our first phase of vaccination.

    He commended  the the United States government for donating 4,000,080 doses of Moderna COVID-19 vaccine, which received in-country on August 1st, 2021 in addition to  the arrival of 177,600 doses of the Johnson and Johnson vaccine which is the first tranche of the almost 40 million doses the Federal Government has procured  from the Africa-Export-Import (AFREXIM) Bank through the African Union.

    He however disclosed that  the balance of the vaccine will be delivered over the coming months.  

    “We sincerely appreciate the AFREXIM Bank President and his team for working tirelessly to ensure that the African countries are not short-changed in the access to the lifesaving COVID-19 vaccines.”

    Furthermore he disclosed that  the Johnson and Johnson vaccine is a one dose effective vaccine, the 177,600 doses will be focused on those who live in the hard-to-reach areas (riverine areas, desert areas, mountainous areas and security-compromised areas) and the elderly. 

    This is because they are people who may find it difficult to leave their homes to the health facility for second dose vaccination, Shuaib explained.  

    In a like manner  today the country is expected to receive another donation of 698,880 doses of the AstraZeneca vaccine from the UK Government through the COVAX facility. 

    The Executive Director of NPHCDA informed that the AstraZenaca doses will be targeted at those that are due for their 2nd dose of the vaccine. 

    “In the next couple of weeks, we will be expecting up to 3.9million doses of the AstraZeneca vaccines to complement what we already have and to ensure that we cover not only those who will be taking their 2nd AstraZeneca vaccine but also for those who will want to take their first dose of this vaccine.”

    “I want to assure Nigerians that all brands of COVID-19 vaccine used in Nigeria are certified by NAFDAC as safe and effective especially against the Delta variant.”

    He urged people who have taken the vaccines to encourage their loved ones, friends, and colleagues to get vaccinated adding that to stop the pandemic, there is need reach at least 70% herd immunity.  

     Even after vaccination, he encouraged the public to  continue to observe the non-pharmaceutical measures such as wearing of facemask, physical distancing, and hand hygiene as a sure way to fight this pandemic.

    The WHO Country Representative to Nigeria, Dr Walter Kazadi Mulombo reiterated the global health agency’s  support to Nigeria for  it’s 2nd phase vaccine roll out for successfully vaccinating over 2,5 million and 1,4 million persons with first dose and second dose of AstraZeneca vaccine.

    Mulombo respectively in the Phase1 rollout of COVID-19 vaccination. More encouraging is the fact that the country utilized 98.9% (3,980,600 doses) of first tranche of COVID-19 vaccines.

    He said, ‘today we are gathered to launch the Phase 2 of COVID-19 vaccination, with an initial 4,000,080 doses of Moderna and 176,000 doses of Johnson and Johnson vaccines, which will be administered to people aged 18 years and above in the 36 states and the Federal Capital Territory of Nigeria.”

    He commended the Government of Nigeria for investing in Cold Chain storage facilities for all vaccines potency, adding that it is a show of commitment to have all citizens  vaccinated against the disease.

    WHO emphazied that most countries, including Nigeria, are currently experiencing the third waves of COVID-19 outbreaks and enjoined the  targeted population to come out and get vaccinated in order to interrupt the community transmission of the disease.

  • FG Receives 177,600 Doses Of J&J Covid-19 Vaccine

    FG Receives 177,600 Doses Of J&J Covid-19 Vaccine

    The Federal Government on Thursday took delivery of 177,600 doses of the Johnson and Johnson vaccine.

    The single-shot J&J vaccine was acquired through the African Vaccine Acquisition Trust (AVAT), with support from Afrexim bank.

    According to the Africa Centre for Disease Control, the vaccines were partly manufactured in Africa.

    The vaccines are expected to be deployed in hard-to-reach areas, to eliminate the need for travel for a second dose.

    More of the J&J vaccines are expected in the country. Health Minister Osagie Ehanire said on Thursday Nigeria has procured nearly 40 million doses of the vaccine through AVAT.

    Nigeria is expected to step up its Covid vaccination program after receiving over four million doses of the Moderna vaccine from the US government last week.

    Only about one percent of the population has been vaccinated, so far.

    The second phase of the national vaccination programme is expected to kick-off next Monday.

  • Nigeria To Receive 176,000 J&J COVID-19 Vaccines On Wednesday

    Nigeria To Receive 176,000 J&J COVID-19 Vaccines On Wednesday

    Nigeria is expected to receive 176,000 doses of the Johnson and Johnson COVID-19 vaccines on Wednesday.

    Executive Director, National Primary Health Care Development Agency, Faisal Shuaib, confirmed this at a news conference in Abuja on Tuesday.

    He said the J&J vaccine, like the AstraZeneca, is safe and efficient against the coronavirus disease, including the deadlier Delta variant.

    The J&J vaccine is a single-shot vaccine.

    It is expected to boost Nigeria’s COVID-19 fight with the Delta variant sparking fears of a third wave of the pandemic.

    Dr. Shuaib had recently announced that the second phase of the COVID-19 vaccination programme would commence soon.

    The exercise had earlier been scheduled to begin on Tuesday, but it was postponed due to “unforeseen circumstances,” according to a spokesperson in the Office of the Secretary to the Government of the Federation, Willie Bassey.

    The need for the rollout of the second batch of the vaccines has, however, become crucial as Nigeria gradually returns to seeing a spike in infections.

    As of Monday, 422 new cases of COVID-19 were recorded in the country, with five more deaths.

    According to the Nigeria Centre for Disease Control (NCDC), the infections were recorded in nine states. Lagos maintained the lead with 190 cases, followed by Rivers (86) and Ogun (85).

    Others are Oyo (22), FCT (20), Kwara (7), Edo (5), Abia (4), and Bayelsa (3)

    So far, a total of 178,508 cases have been confirmed, 165,983 patients have recovered and 2,192 deaths have been recorded in 36 states, including the Federal Capital Territory.

    More than 200 million cases of the pandemic have been confirmed globally, with the death toll reaching four million.

  • Zimbabwe Approves J&J Vaccine As Third Virus Wave Rages

    Zimbabwe Approves J&J Vaccine As Third Virus Wave Rages

    Zimbabwe on Wednesday approved the US-made Johnson and Johnson Covid-19 vaccine for emergency use, the first Western-manufactured jab to be administered in the country amid a spiralling third wave of infections.

    The only vaccines so far approved in the southern African country — which has frosty relationship with some western nations, including the US — are made in China, Russia and India.

    But the government came under fire for turning down an African Union (AU) donation of three million J&J doses in June — citing storage issues and possible side-effects — despite surging cases and vaccine shortages.

    And now, “based on the review of the submitted quality, safety and efficacy data… emergency use authorisation has been granted for (the vaccine) manufactured by Johnson and Johnson,” the Medicines Control Authority of Zimbabwe said in a letter to government seen by journalists on Wednesday.

    Critics had accused the government of refusing the AU donation for political reasons, noting that J&J doses required the same storage temperature as China’s Sinopharm and Sinovac shots.

    Both the US and the European Union have, over the past decade, imposed economic sanctions on Zimbabwean entities and various top officials for alleged rights abuses.

    President Emmerson Mnangagwa last year unsuccessfully asked the United Nations for support in fighting the sanctions, claiming they hurt the country’s economic development.

    Just over 694,600 people in Zimbabwe have been fully vaccinated, while 1.5 million have received a first shot out of a population of 14.8 million.

    A warning this month that people would soon face restrictions if they are not fully immunised sparked a rush to vaccination sites.

    To date, Zimbabwe has recorded more than 70,400 cases of Covid-19, of which at least 3,280 have been fatal.

  • Africa to receive first of 400m Johnson & Johnson vaccines next week

    Africa to receive first of 400m Johnson & Johnson vaccines next week

    Africa, battling a severe third wave of Covid-19 infections, will receive the first batch of 400-million doses of vaccines from Johnson & Johnson next week, the AU’s special envoy on Covid said on Thursday.

    So far, only about 60-million doses have been administered among a total population of 1.3-billion on the 55-nation continent.

    J&J doses will be used to immunise half of the estimated 800-million people in need of the vaccine on the continent, Strive Masiyiwa, who is also the co-ordinator of the AU task force on vaccine acquisition, told an online news conference.

    About six-million doses will be delivered to 27 nations that have paid their share through the end of August, Masiyiwa said. Another 18 are finalising loans from the World Bank and other global lenders before they make payment.

    Deliveries will rise to an average of 10-million a month from September, increasing to 20-million in January until the order is fulfilled by September 2022, he added.

    The balance of the vaccine requirements for the continent will come from Covax, the global vaccine-sharing scheme for poorer nations, as well as bilateral donations from developed nations such as the US, Masiyiwa said.

    J&J, whose vaccine is administered through a single shot, will ship the doses from a facility in SA through its partnership with Aspen Pharmacare, he said.

    Masiyiwa called on pharmaceutical companies to produce vaccines in Africa under licencing arrangements, rather than under contract manufacturing, which critics say prevents countries having vaccine independence.

    “We want to be treated the same way as they produce in India,” Masiyiwa said.

    EU countries have donated less than 3% of the 160-million doses — mostly AstraZeneca shots — that they plan to give to help tame the global pandemic, an EU document shows.

    The small shipments are likely to stir the debate about how wealthy countries are sharing their surplus shots while poor countries still struggle to get supplies.

    The WHO has called on Western governments to donate shots to the Covax programme that it runs with vaccine charity GAVI to ensure fair and equitable distribution to the world’s neediest.

    Many poor countries rely on Covax for their vaccines, but it has so far delivered only 135-million shots globally and the scheme is highly dependent on donated doses. Plans to buy shots on its own were temporarily derailed by vaccine makers’ production problems and export restrictions in India.

    The EU has received enough vaccines to fully inoculate 70% of adults, while SA has given only 7% of its adult population one dose and Nigeria just 1%.

    The EU shipments are also small compared with more than 15-million doses donated by the US and shipped over the past month to countries in Africa, Asia and Latin America as part of the its pledge to give 80-million vaccines. A big portion of those have been through Covax.

    The EU has committed to help inoculate the most vulnerable across the world but, like other wealthy countries, member states have so far focused on buying shots to inoculate their own citizens, contributing to a shortage of vaccines elsewhere.

    EU states, with a combined adult population of 365-million, have so far received about 500-million doses from drugmakers and expect nearly one-billion by the end of September.

    But as of July 13, they had donated less than four-million shots, according to the internal document compiled by the European Commission.

    EU countries have committed to sharing about 160-million doses in total, mostly without preference about their destination, the report says. The tally of shipments and pledged total have not been reported before.

    Brussels has previously said EU nations plan to donate at least 100-million doses by the end of the year. There is no timeline for the target listed in the document.

    Those distributed so far have gone mostly to countries and territories with a link to the donor as member states seek to boost relations with nearby countries and deepen diplomatic ties.

    The EU countries have so far promised to donate almost exclusively AstraZeneca shots, the document shows. J&J is the second-most frequent choice for donations, though a large portion of pledges are for unspecified shots.

    Many EU countries have set limits on the use of the AstraZeneca and J&J vaccines due to concerns about extremely rare blood clotting, reducing the capacity to use them.

    Germany, the EU’s largest country, has committed to donating 33-million doses, the document says, 30-million of which are AstraZeneca and J&J, The remaining three-million have yet to be specified.

    German officials said donations would begin in August and confirmed the numbers and types of vaccines to be donated.

    France is by far the EU’s main donor in terms of pledges. It has promised 60-million doses, mostly to Covax and largely without any preference on their final destination.

    However, it has so far delivered only about 800,000 doses, half of which went to its former colonies, Senegal, Mauritania and Burkina Faso, the document shows.

  • NAFDAC approves emergency use of Johnson & Johnson COVID-19 vaccine

    NAFDAC approves emergency use of Johnson & Johnson COVID-19 vaccine

    The National Agency for Food and Drug Administration and Control (NAFDAC) on Tuesday gave Janssen (Johnson and Johnson) COVID-19 vaccine the nod for conditional emergency use for Nigerians from 18 years

    Director-General of the agency, Prof. Mojisola Adeyeye, made this known in a statement in Abuja.

    She said: “After a thorough evaluation, the NAFDAC vaccine committee concluded that the data on the vaccine were robust and met criteria for efficacy, safety and quality.

    “Thee data also show that the vaccine’s known and potential benefits outweigh its known and potential risks thereby supporting the manufacturer’s recommended use. Janssen COVID-19 Vaccine is the third vaccine recommended in Nigeria for preventing COVID-19.

    “The Janssen COVID-19 vaccine is administered as a single dose. Results from a clinical trial involving people in the United States, South Africa and Latin American countries found that Janssen COVID-19 Vaccine was effective at preventing COVID-19 in people from 18 years of age.

    “The Phase III clinical trial involved over 44,000 people. Half received a single dose of the vaccine and half were given placebo (a dummy injection). People did not know if they had been given Janssen COVID-19 Vaccine or placebo.

    “The trial found a 67 percent reduction in the number of symptomatic COVID-19 cases after 2 weeks in people who received Janssen COVID-19 Vaccine.

    “The most commonly reported side effects were pain at the injection site, headache, fatigue, muscle aches and nausea. Most of these side effects were mild to moderate in severity and lasted 1-2 days.”

    On safety of the vaccine, the NAFDAC boss added: “In line with the NAFDAC’s Pharmacovigilance and safety monitoring plan for COVID-19 vaccines, Janssen COVID-19 vaccine will be closely monitored and subject to several activities that apply specifically to COVID-19 vaccines.

    “Manufacturers are required to provide monthly safety reports in addition to the regular updates generated by NAFDAC activities. Janssen COVID-19 Vaccine works by preparing the body to defend itself against COVID-19.

    “Unopened vaccine vials can be stored and/or transported frozen at -25°C to – 15°C for up to 24 months and 3 months when stored at 2 to 8°C.

    “The Ministry of Health and National Primary Health Care Development Agency will announce when the vaccine becomes available for use in Nigeria.”

  • Nigeria To Receive 29.8 Million Doses Of Johnson & Johnson COVID-19 Vaccine

    Nigeria To Receive 29.8 Million Doses Of Johnson & Johnson COVID-19 Vaccine

    The Nigerian government is expecting about 29.8 million doses of the Johnson & Johnson (J&J) COVID-19 vaccine, Dr Faisal Shuaib said on Monday.

    Shuaib, the Executive Director of the National Primary Health Care Development Agency (NPHCDA), disclosed this at the weekly media briefing of the COVID-19 Presidential Steering Committee in Abuja.

    He added that the government signed off to receive the vaccines through the African Union (AU), while vaccine deliveries through the COVAX facility were expected by the end of May or early June.

    The NPHCDA boss noted that by then, Nigeria would have completed the process of administering the second dose of the AstraZeneca vaccine to those who got the first dose.

    He revealed that the National Agency for Food and Drug Administration and Control (NAFDAC) has continued discussions with manufacturers to examine their vaccines, in anticipation of emergency use listing from the World Health Organisation.

    Shuaib explained that this was to mitigate the negative concerns about the delayed deliveries of AstraZeneca vaccines, thereby ensuring the sustained supply of vaccines for the smooth continuation of the exercise.

    He noted that as of April 26, a total of 1,173, 869 Nigerians, representing 58.3 per cent of the eligible persons targeted in the first phase have received their first dose of the AstraZeneca vaccine.

    The NPHCDA boss, however, decried the global scarcity of COVID-19 vaccines due to high demand, especially in countries where the vaccines were being produced.

    According to him, the government anticipates a delay in vaccine supply to Nigeria which may also affect and impact the remaining phases of the vaccination exercise.